A pharmacologic approach to the use of glyburide in pregnancy

Obstetrics and Gynecology

Volumn 121, Issue 6, 2013, Pages 1309-1312

  Caritis, Steve N ^a   Hebert, Mary F ^a  

^a not available   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; GLIBENCLAMIDE; GLUCOSE; INSULIN; SULFONYLUREA DERIVATIVE;

ARTICLE; DRUG CLEARANCE; DRUG EFFICACY; DRUG TRANSPORT; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN TREATMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; PREGNANCY; PREGNANCY DISORDER; PREGNANT WOMAN; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SINGLE DRUG DOSE;

EID: 84879079198     PISSN: 00297844     EISSN: 1873233X     Source Type: Journal    
DOI: 10.1097/AOG.0b013e31829007f0     Document Type: Article

References (11)

1. Hebert MF, Ma X, Naraharisetti SB, Krudys KM, Umans JG, Hankins GD, et al for the Obstetric-Fetal Pharmacology Research Unit Network. Are we optimizing gestational diabetes treatment with glyburide? the pharmacologic basis for better clinical practice. Clin Pharmacol Ther 2009;85:607-14.
2. Pfizer. Available at: http://www.pfizer.com/files/products/uspi- micronase.pdf. Retrieved April 1, 2013.
3. Rendell M. The role of sulphonylureas in the management of type 2 diabetes mellitus. Drugs 2004;64:1339-58.
4. Sartor G, Lundquist I, Melander A, Scherstén B, Wåhlin-Boll E. Improved effect of glibenclamide on administration before breakfast. Eur J Clin Pharmacol 1982;21:403-8.
5. Sartor G, Melander A, Scherstén B, Wåhlin-Boll E. Serum gliben-clamide in diabetic patients, and influence of food on the kinetics and effects of glibenclamide. Diabetologia 1980;18:17-22.
6. Go EH, Kyriakidou-Himonas M, Berelowitz M. Effects of glipizide GITS and glibenclamide on metabolic control, hepatic glucose production, and insulin secretion in patients with type 2 diabetes. Diabetes Metab Res Rev 2004;20:225-31.
7. Rydberg T, Jönsson A, Røder M, Melander A. Hypoglycemic activity of glyburide (glibenclamide) metabolites in humans. Diabetes Care 1994;17:1026-30.
8. Groop L, Wåhlin-Boll E, Groop PH, Tötterman KJ, Melander A, Tolppanen EM, et al. Pharmacokinetics and metabolic effects of glibenclamide and glipizide in type 2 diabetics. Eur J Clin Pharmacol 1985;28:697-704.
9. Melander A, Donnelly R, Rydberg T. Is there a concentration-effect relationship for sulphonylureas? Clin Pharmacokinet 1998;34:181-8.
10. Langer O, Conway DL, Berkus MD, Xenakis EM, Gonzales O. A comparison of glyburide and insulin in women with gestational diabetes mellitus. N Engl J Med 2000;343:1134-8.
11. Nicholson W, Baptiste-Roberts K. Oral hypoglycaemic agents during pregnancy: the evidence for effectiveness and safety. Best Pract Res Clin Obstet Gynaecol 2011;25:51-63. Human Development Human Development